Journal of Heart and Lung Transplantation

Article	Citations
COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal	1206
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation	297
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult lung transplantation report — 2021; Focus on recipient charact	215
A 5-year single-center early experience of heart transplantation from donation after circulatory-determined death donors	150
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult heart transplantation report—2020; focus on deceased donor characterist	145
First cases of COVID-19 in heart transplantation from China	134
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult heart transplantation report — 2021; Focus on recipient charac	131
BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response	109
Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry	106
Early US experience with cardiac donation after circulatory death (DCD) using normothermic regional perfusion	103
Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients	101
Updated definitions of adverse events for trials and registries of mechanical circulatory support: A consensus statement of the mechanical circulatory support academic research consortium	99
Donor heart and lung procurement: A consensus statement	98
Early experience with the HeartMate 3 continuous-flow ventricular assist device in pediatric patients and patients with congenital heart disease: A multicenter registry analysis	83
The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients	83
MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry	75
Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience	73
Respiratory viral infection in lung transplantation induces exosomes that trigger chronic rejection	71
COVID-19: Yet another coronavirus challenge in transplantation	70
Gut microbiota, endotoxemia, inflammation, and oxidative stress in patients with heart failure, left ventricular assist device, and transplant	65
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult lung transplantation report — 2020; focus on deceased donor characteris	60
Left ventricular assist systems and infection-related outcomes: A comprehensive analysis of the MOMENTUM 3 trial	58
Epidemiologic and clinical characteristics of heart transplant recipients during the 2019 coronavirus outbreak in Wuhan, China: A descriptive survey report	58
Donor fraction cell-free DNA and rejection in adult and pediatric heart transplantation	57
ISHLT consensus statement on donor organ acceptability and management in pediatric heart transplantation	55

Artificial intelligence for early prediction of pulmonary hypertension using electrocardiography	55
Pig-to-non-human primate heart transplantation: The final step toward clinical xenotransplantation?	55
Circulating extracellular vesicles as non-invasive biomarker of rejection in heart transplant	53
Mortality in patients with cardiogenic shock supported with VA ECMO: A systematic review and meta-analysis evaluating the impact of etiology on 29,289 patients	53
SARS-CoV-2 messenger RNA vaccine antibody response and reactogenicity in heart and lung transplant recipients	49
Utilization of hepatitis C virus–infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement	48
COVID-19 vaccination in our transplant recipients: The time is now	47
Impact of left ventricular assist device implantation on mitral regurgitation: An analysis from the MOMENTUM 3 trial	46
Heart transplantation following donation after circulatory death: Expanding the donor pool	44
Risk assessment of chronic lung allograft dysfunction phenotypes: Validation and proposed refinement of the 2019 International Society for Heart and Lung Transplantation classification system	44
International Society for Heart and Lung Transplantation consensus statement for the standardization of bronchoalveolar lavage in lung transplantation	42
Update to an early investigation of outcomes with the new 2018 donor heart allocation system in the United States	42
The impact of frailty on mortality after heart transplantation	40
Increased early acute cellular rejection events in hepatitis C-positive heart transplantation	39
ISHLT consensus statement for the selection and management of pediatric and congenital heart disease patients on ventricular assist devices Endorsed by the American Heart Association	39
Berlin Heart EXCOR and ACTION post-approval surveillance study report	38
Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study	38
Lung transplantation for cystic fibrosis	36
Coronavirus disease 2019 in heart transplant recipients: Risk factors, immunosuppression, and outcomes	36
Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT	36
Systemic ventricular assist device support in Fontan patients: A report by ACTION	36
The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10- Year Update	35
Donor-derived cell-free DNA accurately detects acute rejection in lung transplant patients, a multicenter cohort study	35
Right ventricular function and cardiopulmonary performance among patients with heart failure supported by durable mechanical circulatory support devices	34
COVID-19 in a lung transplant recipient	34
Improved survival after heart transplantation in patients bridged with extracorporeal membrane oxygenation in the new allocation system	33
Effect of aspirin dose on hemocompatibility-related outcomes with a magnetically levitated left ventricular assist device: An analysis from the MOMENTUM 3 study	32
The results of a single-center experience with HeartMate 3 in a biventricular configuration	32
Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy	32
Is it too early to investigate survival outcomes of the new US heart allocation system?	32
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-ninth adult lung transplantation report—2022; focus on lung transplant reci	32
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth pediatric heart transplantation report — 2021; focus on recipient ch	31
First in man evaluation of a novel circulatory support device: Early experience with the Impella 5.5 after CE mark approval in Germany	31
COVID-19 in a pediatric heart transplant recipient: Emergence of donor-specific antibodies	31
Outcomes in the 2018 UNOS donor heart allocation system: A perspective on disparate analyses	30
Ethical considerations regarding heart and lung transplantation and mechanical circulatory support during the COVID-19 pandemic: an ISHLT COVID-19 Task Force statement	30
Pregnancy outcomes in heart transplant recipients	30
Clinical implications of idiopathic pulmonary arterial hypertension phenotypes defined by cluster analysis	30
Short- and long-term adverse events in patients on temporary circulatory support before durable ventricular assist device: An IMACS registry analysis	30
Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension	29
Less invasive surgical implant strategy and right heart failure after LVAD implantation	28
Cell-free DNA beyond a biomarker for rejection: Biological trigger of tissue injury and potential therapeutics	28
Donor heart selection: Evidence-based guidelines for providers	28
Pregnancy in pulmonary arterial hypertension: Midterm outcomes of mothers and offspring	28
Prediction of donor related lung injury in clinical lung transplantation using a validated ex vivo lung perfusion inflammation score	27
Cell death and ischemia-reperfusion injury in lung transplantation	27
Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial	27
Clinical outcomes and healthcare expenditures in the real world with left ventricular assist devices – The CLEAR-LVAD study	26
Mitochondrial transplantation for myocardial protection in ex-situ‒perfused hearts donated after circulatory death	26
A case series of novel coronavirus infection in heart transplantation from 2 centers in the pandemic area in the North of Italy	26

Long-term outcomes after intraoperative extracorporeal membrane oxygenation during lung transplantation	26
Use of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD)	26
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 23rd pediatric heart transplantation report—2020; focus on deceased donor characte	25
Expanding Heart Transplants from Donors After Circulatory Death (DCD) - Results of the First Randomized Controlled Trial Using the Organ Care System (OCS™) Heart - (OCS DCD Heart Trial)	25
Challenges in heart transplantation during COVID-19: A single-center experience	25
Incidence and impact of primary graft dysfunction in adult heart transplant recipients: A systematic review and meta-analysis	25
Circulating exosomes with lung self-antigens as a biomarker for chronic lung allograft dysfunction: A retrospective analysis	24
Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension	24
COVID-19 vaccination immune paresis in heart and lung transplantation	24
Ex situ heart perfusion: The past, the present, and the future	23
The International Society for Heart and Lung Transplantation/Heart Failure Society of America Guideline on Acute Mechanical Circulatory Support	23
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth pediatric lung transplantation report — 2021; Focus on recipient cha	23
Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort	23
Bridging the survival gap in cystic fibrosis: An investigation of lung transplant outcomes in Canada and the United States	23
Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction	22
Variability in donor organ offer acceptance and lung transplantation survival	22
Clinical myocardial recovery in advanced heart failure with long term left ventricular assist device support	22
Serial right heart catheter assessment between balloon pulmonary angioplasty sessions identify procedural factors that influence response to treatment	22
Percutaneous versus surgical cannulation for femoro-femoral VA-ECMO in patients with cardiogenic shock: Results from the Extracorporeal Life Support Organization Registry	22
Many heart transplant biopsies currently diagnosed as no rejection have mild molecular antibody-mediated rejection-related changes	22
Comparison of combined heart‒liver vs heart-only transplantation in pediatric and young adult Fontan recipients	21
Collapsing glomerulopathy associated with COVID-19 infection in a heart transplant recipient	21
Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis	21
The International thoracic organ transplant registry of the international society for heart and lung transplantation: Thirty-ninth adult heart transplantation report—2022; focus on transplant for rest	21
International consensus recommendations for anesthetic and intensive care management of lung transplantation. An EACTAIC, SCA, ISHLT, ESOT, ESTS, and AST approved document	21
Impact of race on survival in pulmonary arterial hypertension: Results from the REVEAL registry	21
Transplanting thoracic COVID-19 positive donors: An institutional protocol and report of the first 14 cases	21
Clinical utility of donor-derived cell-free DNA testing in cardiac transplantation	21
Impact of carfilzomib-based desensitization on heart transplantation of sensitized candidates	20
A novel method of donor‒recipient size matching in pediatric heart transplantation: A total cardiac volume‒predictive model	20
Preservation by cold storage vs ex vivo normothermic perfusion of marginal donor hearts: clinical, histopathologic, and ultrastructural features	20
Risk factors for mortality in lung transplant recipients aged ≥65 years: A retrospective cohort study of 5,815 patients in the scientific registry of transplant recipients	20
Epicardial transplantation of atrial appendage micrograft patch salvages myocardium after infarction	20
Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study	20
Bronchoalveolar bile acid and inflammatory markers to identify high-risk lung transplant recipients with reflux and microaspiration	20
Gender and racial disparities in lung transplantation in the United States	20
Interest of TAPSE/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment	20
Elevated pulmonary arterial elastance and right ventricular uncoupling are associated with greater mortality in advanced heart failure	20
Circulating miR-181a-5p as a new biomarker for acute cellular rejection in heart transplantation	20
CFTR modulator use in post lung transplant recipients	19
Donor-derived cell-free DNA as a composite marker of acute lung allograft dysfunction in clinical care	19
Azithromycin prophylaxis after lung transplantation is associated with improved overall survival	19
Long-term survival on LVAD support: Device complications and end-organ dysfunction limit long-term success	19
Pig heart and lung xenotransplantation: Present status	19
Ex vivo treatment of cytomegalovirus in human donor lungs using a novel chemokine-based immunotoxin	19
Clinical impact of concomitant tricuspid valve procedures during left ventricular assist device implantation	19
Aspiration of conjugated bile acids predicts adverse lung transplant outcomes and correlates with airway lipid and cytokine dysregulation	18
Percutaneous RVAD with the Protek Duo for severe right ventricular primary graft dysfunction after heart transplant	18
Lung transplantation for idiopathic pulmonary fibrosis enriches for individuals with telomere-mediated disease	18
Use of metabolomics to identify strategies to improve and prolong ex vivo lung perfusion for lung transplants	18
Recipient and surgical factors trigger severe primary graft dysfunction after heart transplant	18
Therapeutic efficacy of large aligned cardiac tissue derived from induced pluripotent stem cell in a porcine ischemic cardiomyopathy model	17
Clinical characteristics, management practices, and outcomes among lung transplant patients with COVID-19	17
ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery	17
Outcomes based on blood pressure in patients on continuous flow left ventricular assist device support: An Interagency Registry for Mechanically Assisted Circulatory Support analysis	17
Molecular T-cell‒mediated rejection in transbronchial and mucosal lung transplant biopsies is associated with future risk of graft loss	17
The International thoracic organ transplant registry of the international society for heart and lung transplantation: Twenty-fifth pediatric heart transplantation report—2022; focus on infant heart tr	17
Riociguat and balloon pulmonary angioplasty improve prognosis in patients with inoperable chronic thromboembolic pulmonary Hypertension	17
Venous or arterial thromboses after venoarterial extracorporeal membrane oxygenation support: Frequency and risk factors	17
Glycation of ryanodine receptor in circulating lymphocytes predicts the response to cardiac resynchronization therapy	17
The lung microbiome in lung transplantation	17
A current era analysis of ABO incompatible listing practice and impact on outcomes in young children requiring heart transplantation	16
Risk factors of invasive fungal infections in lung transplant recipients: A systematic review and meta-analysis	16
The effect of COVID-19 on transplant function and development of CLAD in lung transplant patients: A multicenter experience	16
An extracellular oxygen carrier during prolonged pulmonary preservation improves post-transplant lung function	16
The influence of mechanical Circulatory support on post-transplant outcomes in pediatric patients: A multicenter study from the International Society for Heart and Lung Transplantation (ISHLT) Registr	16
Adenosine A2A receptor agonist (regadenoson) in human lung transplantation	16
Initial bridge to transplant experience with a bioprosthetic autoregulated artificial heart	16
Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review	16
Incidence and long-term outcome of heart transplantation patients who develop postoperative renal failure requiring dialysis	16
Influence of the donor history of tobacco and marijuana smoking on early and intermediate lung transplant outcomes	16
Quantifying the impact from stroke during support with continuous flow ventricular assist devices: An STS INTERMACS analysis	16
Innate allorecognition in transplantation	16
Outcomes after heart transplantation and total artificial heart implantation: A multicenter study	16
Cystic fibrosis foundation consensus statements for the care of cystic fibrosis lung transplant recipients	15
A novel donor-derived cell-free DNA assay for the detection of acute rejection in heart transplantation	15
Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry	15
Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?	15
The impaired diaphragmatic function after bilateral lung transplantation: A multifactorial longitudinal study	15
Reproductive health after thoracic transplantation: An ISHLT expert consensus statement	15

Exercise right ventricular ejection fraction predicts right ventricular contractile reserve	15
Successful salvage therapy for fungal bronchial anastomotic infection after –lung transplantation with an inhaled triazole anti-fungal PC945	15
Arterial oxygen and carbon dioxide tension and acute brain injury in extracorporeal cardiopulmonary resuscitation patients: Analysis of the extracorporeal life support organization registry	15
Rotational thromboelastometry reduces blood loss and blood product usage after lung transplantation	15
A challenge to equity in transplantation: Increased center-level variation in short-term mechanical circulatory support use in the context of the updated U.S. heart transplant allocation policy	15
Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis	15
Surveillance for cardiac allograft vasculopathy: Practice variations among 50 pediatric heart transplant centers	15
Dilemma of organ donation in transplantation and the COVID-19 pandemic	15
Use of direct oral anticoagulants after heart transplantation	14
MicroRNA-206 antagomiR‒enriched extracellular vesicles attenuate lung ischemia‒reperfusion injury through CXCL1 regulation in alveolar epithelial cells	14
Effects of cold or warm ischemia and ex-vivo lung perfusion on the release of damage associated molecular patterns and inflammatory cytokines in experimental lung transplantation	14
Risk assessment in severe pulmonary hypertension due to interstitial lung disease	14
Bronchiolitis obliterans syndrome is associated with increased senescent lymphocytes in the small airways	14
High torque tenovirus (TTV) load before first vaccine dose is associated with poor serological response to COVID-19 vaccination in lung transplant recipients	14
Extended post ex-vivo lung perfusion cold preservation predicts primary graft dysfunction and mortality: Results from a multicentric study	14
Myocardial edema in COVID-19 on cardiac MRI	14
ISHLT position paper on thoracic organ transplantation in controlled donation after circulatory determination of death (cDCD)	14
Lactate during ex-situ heart perfusion does not predict the requirement for mechanical circulatory support following donation after circulatory death (DCD) heart transplants	14
Predicted heart mass–based size matching among recipients with moderate pulmonary hypertension: Outcomes and sex effect	14
Immune checkpoint inhibitors in heart or lung transplantation: Early results from a registry initiative	14
Right ventricular adaptation to pressure-overload: Differences between chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension	14
Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age	14
Pediatric heart transplantation following donation after circulatory death, distant procurement, and ex-situ perfusion	14
A CLUE for better assessment of donor lungs: Novel technique in clinical ex vivo lung perfusion	14
Incidence and outcome of post-transplant lymphoproliferative disorders in lung transplant patients: Analysis of ISHLT Registry	14
Two-year outcome of warfarin monotherapy in HeartMate 3 left ventricular assist device: A single-center experience	14
Impact of thoracotomy approach on right ventricular failure and length of stay in left ventricular assist device implants: an intermacs registry analysis	13
Right ventricular area strain from 3-dimensional echocardiography: Mechanistic insight of right ventricular dysfunction in pediatric pulmonary hypertension	13
Monitoring of perfusion quality and prediction of donor heart function during ex-vivo machine perfusion by myocardial microcirculation versus surrogate parameters	13
A clinical and cost-effectiveness analysis of the HeartMate 3 left ventricular assist device for transplant-ineligible patients: A United Kingdom perspective	13
Understanding risk factors and predictors for stroke subtypes in the ENDURANCE trials	13
Intravenous iron supplement for iron deficiency in cardiac transplant recipients (IronIC): A randomized clinical trial	13
Indications and outcome after lung transplantation in children under 12 years of age: A 16-year single center experience	13
Operating room extubation: A predictive factor for 1-year survival after double-lung transplantation	13
Torque teno virus DNA load as a predictive marker of antibody response to a three-dose regimen of COVID-19 mRNA-based vaccine in lung transplant recipients	13
Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis	13
Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations	13
Incremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension	13
Donor derived cell free DNA% is elevated with pathogens that are risk factors for acute and chronic lung allograft injury	13
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-third pediatric lung transplantation report — 2020; focus on deceased donor	13
Ventilation in the prone position improves oxygenation and results in more lungs being transplanted from organ donors with hypoxemia and atelectasis	12
The impact of pre-implant illness severity on the outcomes of pediatric patients undergoing durable ventricular assist device	12
Preventing alloimmune rejection using circular RNA FSCN1-silenced dendritic cells in heart transplantation	12
Pulmonary artery pulsatility index as a predictor of right ventricular failure in left ventricular assist device recipients: A systematic review	12
Unmasking right ventricular-arterial uncoupling during fluid challenge in pulmonary hypertension	12
Temporal shift and predictive performance of machine learning for heart transplant outcomes	12
Early report from the Pediatric Heart Transplant Society on COVID-19 infections in pediatric heart transplant candidates and recipients	12
Proteomic profiling identifies CLEC4C expression as a novel biomarker of primary graft dysfunction after heart transplantation	12
Interplay of sex hormones and long-term right ventricular adaptation in a Dutch PAH-cohort	12
Donor thyroid hormone therapy and heart transplantation outcomes: ISHLT transplant registry analysis	12
A simplified strategy for donor-recipient size-matching in lung transplant for interstitial lung disease	12
Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation	12
LVAD decommissioning for myocardial recovery: Long-term ventricular remodeling and adverse events	12
International experience using a durable, centrifugal-flow ventricular assist device for biventricular support	12
Risk assessment in pulmonary hypertension based on routinely measured laboratory parameters	12
Complications of balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: Impact on the outcome	12
Platelet aggregation and response to aspirin therapy in cardiac allograft vasculopathy	12
COVID-19 leading to acute encephalopathy in a patient with heart transplant	12
Contemporary trends in PGD incidence, outcomes, and therapies	12
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: Initial report from a cardiometabolic center of excellence	12
ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part I: Epidemiology, assessment of extrapulmonary conditions, candidate evaluation, selection criteria, an	12
Early United States experience with lung donation after circulatory death using thoracoabdominal normothermic regional perfusion	12
WITHDRAWN: Executive Summary - The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients	12
Right single lung transplantation or double lung transplantation compared with left single lung transplantation in chronic obstructive pulmonary disease	11
Biology of myocardial recovery in advanced heart failure with long-term mechanical support	11
Circulating microRNAs in cellular and antibody-mediated heart transplant rejection	11
Cardiac allograft vasculopathy and secondary outcomes of hepatitis C-positive donor hearts at 1 year after transplantation	11
Association between recipient blood type and heart transplantation outcomes in the United States	11
Bridging to transplant with HeartMate 3 left ventricular assist devices in the new heart organ allocation system: An individualized approach	11
Comparison of de novo donor-specific antibodies between living and cadaveric lung transplantation	11
Putting ethics and clinical decision making before politics: requiring COVID-19 immunization for Solid Organ Transplantation (SOT) Candidates and their Support Team	11
Safety of reduced anti-thrombotic strategy in patients with HeartMate 3 left ventricular assist device	11
The heart–gut microbiome axis in advanced heart failure	11
Remote ex vivo lung perfusion at a centralized evaluation facility	11
Racial and socioeconomic disparities in pediatric heart transplant outcomes in the era of anti-thymocyte globulin induction	11
Machine-learning–based exploration to identify remodeling patterns associated with death or heart-transplant in pediatric-dilated cardiomyopathy	11
Immunologic risk stratification of pediatric heart transplant patients by combining HLAMatchmaker and PIRCHE-II	11
The introduction of a super-urgent heart allocation scheme in the UK: A 2-year review	11
Innate immunity in lung transplantation	11
Precise treatment of acute antibody-mediated cardiac allograft rejection in rats using C4d-targeted microbubbles loaded with nitric oxide	11
Intravenous bevacizumab as a novel treatment for refractory left ventricular assist device-related gastrointestinal bleeding	11
Temporal trends in the use and outcomes of temporary mechanical circulatory support as a bridge to cardiac transplantation in Spain. Final report of the ASIS-TC study	11
Approaches to the Management of Sensitized Lung Transplant Candidates: Findings from an International Survey	11
Heart retransplantation following COVID-19 illness in a heart transplant recipient	11
Inflammatory responses in lungs from donation after brain death: Mechanisms and potential therapeutic targets	11
Higher levels of allograft injury in black patients early after heart transplantation	11
First Results of Soprano: Macitentan in Patients (pts) with Pulmonary Hypertension (PH) Post-Left Ventricular Assist Device (LVAD) Implantation	11
Incorporation of renal function in mortality risk assessment for pulmonary arterial hypertension	11
Stroke in pediatric ventricular assist device patients—a pedimacs registry analysis	11
Lung transplant outcome following donation after euthanasia	11
Hemodynamic reserve predicts early right heart failure after LVAD implantation	10
Patient factors associated with left ventricular assist device infections: A scoping review	10
Lung transplantation disparities based on diagnosis for patients bridging to transplant on extracorporeal membrane oxygenation	10
Residual mitral regurgitation in patients with left ventricular assist device support – An INTERMACS analysis	10
Full recovery of right ventricular systolic function in children undergoing bilateral lung transplantation for severe PAH	10